

Justin A Ezekowitz

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3700036/publications.pdf>

Version: 2024-02-01

361
papers

35,811
citations

12597

71
h-index

4414

178
g-index

370
all docs

370
docs citations

370
times ranked

29759
citing authors

#	ARTICLE	IF	CITATIONS
1	Cardiac and cardiometabolic phenotyping of trastuzumab-mediated cardiotoxicity: a secondary analysis of the MANTICORE trial. <i>European Heart Journal - Cardiovascular Pharmacotherapy</i> , 2022, 8, 130-139.	1.4	24
2	Prevalence of Cardiovascular Disease in a Population-Based Cohort of High-Cost Healthcare Services Users. <i>CJC Open</i> , 2022, 4, 180-188.	0.7	2
3	The Incidence and Prevalence of Cardiac Amyloidosis in a Large Community-Based Cohort in Alberta, Canada. <i>Journal of Cardiac Failure</i> , 2022, 28, 237-246.	0.7	5
4	Concurrent use of P-glycoprotein or Cytochrome 3A4 drugs and non-vitamin K antagonist oral anticoagulants in non-valvular atrial fibrillation. <i>European Heart Journal Quality of Care & Clinical Outcomes</i> , 2022, 8, 195-201.	1.8	5
5	Heterogeneity of diabetes as a risk factor for major adverse cardiovascular events in anticoagulated patients with atrial fibrillation: an analysis of the ARISTOTLE trial. <i>European Heart Journal - Cardiovascular Pharmacotherapy</i> , 2022, 8, 227-235.	1.4	6
6	Cluster Analysis of Cardiovascular Phenotypes in Patients With Type 2 Diabetes and Established Atherosclerotic Cardiovascular Disease: A Potential Approach to Precision Medicine. <i>Diabetes Care</i> , 2022, 45, 204-212.	4.3	25
7	Automated interpretation of systolic and diastolic function on the echocardiogram: a multicohort study. <i>The Lancet Digital Health</i> , 2022, 4, e46-e54.	5.9	62
8	Exploring the pragmatic-explanatory spectrum across cardiovascular clinical trials. <i>Contemporary Clinical Trials</i> , 2022, 113, 106646.	0.8	3
9	2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. <i>European Journal of Heart Failure</i> , 2022, 24, 4-131.	2.9	820
10	Medical Therapy During Hospitalization for Heart Failure With Reduced Ejection Fraction: The VICTORIA Registry. <i>Journal of Cardiac Failure</i> , 2022, 28, 1063-1077.	0.7	23
11	Heart failure with mildly reduced ejection fraction: retrospective study of ejection fraction trajectory risk. <i>ESC Heart Failure</i> , 2022, 9, 1564-1573.	1.4	3
12	Developments in Exercise Capacity Assessment in Heart Failure Clinical Trials and the Rationale for the Design of METEORIC-HF. <i>Circulation: Heart Failure</i> , 2022, 15, CIRCHEARTFAILURE121008970.	1.6	8
13	Fluid Restriction: Time to Let it Flow?. <i>Journal of Cardiac Failure</i> , 2022, 28, 1480-1481.	0.7	3
14	Reduction of dietary sodium to less than 100 mmol in heart failure (SODIUM-HF): an international, open-label, randomised, controlled trial. <i>Lancet, The</i> , 2022, 399, 1391-1400.	6.3	67
15	Nationwide study of sex differences in incident heart failure in newly diagnosed nonvalvular atrial fibrillation. <i>CJC Open</i> , 2022, , .	0.7	0
16	Assessing race and ethnicity differences in outcomes based on GDMT and target NT-proBNP in patients with heart failure with reduced ejection fraction: An analysis of the GUIDE-IT study. <i>Progress in Cardiovascular Diseases</i> , 2022, , .	1.6	1
17	Epidemiology of Worsening Heart Failure in a Population-based Cohort from Alberta, Canada: Evaluating Eligibility for Treatment With Vericiguat. <i>Journal of Cardiac Failure</i> , 2022, 28, 1298-1308.	0.7	8
18	Clinical Prediction Models for Heart Failure Hospitalization in Type 2 Diabetes: A Systematic Review and Meta-Analysis. <i>Journal of the American Heart Association</i> , 2022, 11, e024833.	1.6	7

#	ARTICLE	IF	CITATIONS
19	Vericiguat and Health-Related Quality of Life in Patients With Heart Failure With Reduced Ejection Fraction: Insights From the VICTORIA Trial. <i>Circulation: Heart Failure</i> , 2022, 15, .	1.6	10
20	Clinical risk, sociodemographic factors, and SARS-CoV-2 infection over time in Ontario, Canada. <i>Scientific Reports</i> , 2022, 12, .	1.6	8
21	Left atrial remodelling, mid-regional pro-atrial natriuretic peptide, and prognosis across a range of ejection fractions in heart failure. <i>European Heart Journal Cardiovascular Imaging</i> , 2021, 22, 220-228.	0.5	10
22	Physician Perspectives on the Diagnosis and Management of Heart Failure With Preserved Ejection Fraction. <i>CJC Open</i> , 2021, 3, 361-366.	0.7	5
23	Plasma Volume Status and Its Association With In-Hospital and Postdischarge Outcomes in Decompensated Heart Failure. <i>Journal of Cardiac Failure</i> , 2021, 27, 297-308.	0.7	4
24	Evidence-Based Management of Acute Heart Failure. <i>Canadian Journal of Cardiology</i> , 2021, 37, 621-631.	0.8	16
25	CCS/CHFS Heart Failure Guidelines Update: Defining a New Pharmacologic Standard of Care for Heart Failure With Reduced Ejection Fraction. <i>Canadian Journal of Cardiology</i> , 2021, 37, 531-546.	0.8	170
26	Association between Respiratory Failure and Clinical Outcomes in Patients with Acute Heart Failure: Analysis of 5 Pooled Clinical Trials. <i>Journal of Cardiac Failure</i> , 2021, 27, 602-606.	0.7	13
27	Differences in NT-proBNP Response and Prognosis in Men and Women With Heart Failure With Reduced Ejection Fraction. <i>Journal of the American Heart Association</i> , 2021, 10, e019712.	1.6	6
28	Randomized Placebo-Controlled Trial of Ferric Carboxymaltose in Heart Failure With Iron Deficiency: Rationale and Design. <i>Circulation: Heart Failure</i> , 2021, 14, e008100.	1.6	30
29	Sex Differences in Clinical Course and Patient-Reported Outcomes Among Patients Hospitalized for Heart Failure. <i>JACC: Heart Failure</i> , 2021, 9, 336-345.	1.9	23
30	Health-Related Quality of Life and Mortality in Heart Failure: The Global Congestive Heart Failure Study of 23 000 Patients From 40 Countries. <i>Circulation</i> , 2021, 143, 2129-2142.	1.6	101
31	Feasibility of Incorporating Voice Technology and Virtual Assistants in Cardiovascular Care and Clinical Trials. <i>Current Cardiovascular Risk Reports</i> , 2021, 15, 13.	0.8	8
32	Intercountry Differences in Guideline-Directed Medical Therapy and Outcomes Among Patients With Heart Failure. <i>JACC: Heart Failure</i> , 2021, 9, 497-505.	1.9	5
33	Cost-Utility of Catheter Ablation for Atrial Fibrillation in Patients with Heart Failure: An Economic Evaluation. <i>Journal of the American Heart Association</i> , 2021, 10, e019599.	1.6	13
34	Effect of patient-centered transitional care services on patient-reported outcomes in heart failure: sex-specific analysis of the <sc>PACT-HF</sc> randomized controlled trial. <i>European Journal of Heart Failure</i> , 2021, 23, 1488-1498.	2.9	22
35	Effect of Sotagliflozin on Total Hospitalizations in Patients With Type 2 Diabetes and Worsening Heart Failure. <i>Annals of Internal Medicine</i> , 2021, 174, 1065-1072.	2.0	32
36	Hemoglobin and Clinical Outcomes in the Vericiguat Global Study in Patients With Heart Failure and Reduced Ejection Fraction (VICTORIA). <i>Circulation</i> , 2021, 144, 1489-1499.	1.6	21

#	ARTICLE	IF	CITATIONS
37	Residuals. <i>Circulation</i> , 2021, 144, 438-440.	1.6	1
38	Participation in a Heart Failure Clinical Trial. <i>Circulation: Heart Failure</i> , 2021, 14, e008242.	1.6	12
39	2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. <i>European Heart Journal</i> , 2021, 42, 3599-3726.	1.0	5,558
40	Impact of Atrial Fibrillation Case Volume in the Emergency Department on Early and Late Outcomes of Patients With New Atrial Fibrillation. <i>Annals of Emergency Medicine</i> , 2021, 78, 242-252.	0.3	3
41	Clinical Phenotypes in Patients With Type 2 Diabetes Mellitus: Characteristics, Cardiovascular Outcomes and Treatment Strategies. <i>Current Heart Failure Reports</i> , 2021, 18, 253-263.	1.3	6
42	Sex-Differences in Cause of Death for Patients Hospitalized for Heart Failure With Reduced Versus Preserved Ejection Fraction (from the ASCEND-HF Trial). <i>American Journal of Cardiology</i> , 2021, 154, 123-126.	0.7	1
43	Is There Any Interaction Between Sex and Renal Function Change During Hospital Stay in Patients Hospitalized With Acute Heart Failure?. <i>Journal of Cardiac Failure</i> , 2021, 27, 934-941.	0.7	0
44	Cardiac remodelling predicts outcome in patients with chronic heart failure. <i>ESC Heart Failure</i> , 2021, 8, 5352-5362.	1.4	12
45	Clinical Outcome Predictions for the Vericiguat Global Study in Subjects With Heart Failure With Reduced Ejection Fraction (VICTORIA) Trial. <i>Journal of Cardiac Failure</i> , 2021, 27, 949-956.	0.7	8
46	Chloride in Heart Failure. <i>JACC: Heart Failure</i> , 2021, 9, 904-915.	1.9	22
47	Blood Pressure and Safety Events With Vericiguat in the VICTORIA Trial. <i>Journal of the American Heart Association</i> , 2021, 10, e021094.	1.6	23
48	The influence of comorbidities on achieving an N-terminal pro-B-type natriuretic peptide target: a secondary analysis of the GUIDE-IT trial. <i>ESC Heart Failure</i> , 2021, , .	1.4	3
49	Ambulance use, distance and outcomes in patients with suspected cardiovascular disease: a registry-based geographic information system study. <i>European Heart Journal: Acute Cardiovascular Care</i> , 2020, 9, 45-58.	0.4	14
50	Role of Sodium-Glucose Cotransporter-2 Inhibition in the Treatment of Adults With Heart Failure. <i>Canadian Journal of Diabetes</i> , 2020, 44, 103-110.	0.4	2
51	Management of Comorbidities in Heart Failure. , 2020, , 687-696.e2.		0
52	All for one, but not one for all. <i>European Heart Journal</i> , 2020, 41, 642-644.	1.0	1
53	OUTSMART HF. <i>Circulation</i> , 2020, 141, 818-827.	1.6	19
54	Design and Region-Specific Adaptation of the Dietary Intervention Used in the SODIUM-HF Trial: A Multicentre Study. <i>CJC Open</i> , 2020, 2, 8-14.	0.7	5

#	ARTICLE	IF	CITATIONS
55	Impact of cardiology follow-up care on treatment and outcomes of patients with new atrial fibrillation discharged from the emergency department. <i>Europace</i> , 2020, 22, 695-703.	0.7	22
56	Eligibility of sodium-glucose cotransporter-2 inhibitors among patients with diabetes mellitus admitted for heart failure. <i>ESC Heart Failure</i> , 2020, 7, 275-279.	1.4	6
57	N-Terminal Pro-B-Type Natriuretic Peptide and Clinical Outcomes. <i>JACC: Heart Failure</i> , 2020, 8, 931-939.	1.9	88
58	Effect of Vericiguat vs Placebo on Quality of Life in Patients With Heart Failure and Preserved Ejection Fraction. <i>JAMA - Journal of the American Medical Association</i> , 2020, 324, 1512.	3.8	170
59	Is There a Sex Gap in Surviving an Acute Coronary Syndrome or Subsequent Development of Heart Failure?. <i>Circulation</i> , 2020, 142, 2231-2239.	1.6	39
60	Layer-specific strain in patients with heart failure using cardiovascular magnetic resonance: not all layers are the same. <i>Journal of Cardiovascular Magnetic Resonance</i> , 2020, 22, 81.	1.6	21
61	Non-vitamin K antagonist oral anticoagulant (NOAC) use and dosing in Canadian practice: Insights from the optimising pharmacotherapy in the management approach to lowering risk in atrial fibrillation (OPTIMAL AF) Programme. <i>International Journal of Clinical Practice</i> , 2020, 74, e13625.	0.8	5
62	Change of Health-Related Quality of Life Over Time and Its Association With Patient Outcomes in Patients With Heart Failure. <i>Journal of the American Heart Association</i> , 2020, 9, e017278.	1.6	23
63	Comparative Effectiveness of Primary Prevention Implantable Cardioverter-Defibrillators in Older Heart Failure Patients With Diabetes Mellitus. <i>Journal of the American Heart Association</i> , 2020, 9, e012405.	1.6	2
64	Low Prevalence of Transcatheter Mitral Valve Repair Eligibility in a Community Heart Failure Population. <i>Circulation: Heart Failure</i> , 2020, 13, e006952.	1.6	4
65	Optimizing Access to Heart Failure Care in Canada During the COVID-19 Pandemic. <i>Canadian Journal of Cardiology</i> , 2020, 36, 1148-1151.	0.8	19
66	Conducting clinical trials in heart failure during (and after) the COVID-19 pandemic: an Expert Consensus Position Paper from the Heart Failure Association (HFA) of the European Society of Cardiology (ESC). <i>European Heart Journal</i> , 2020, 41, 2109-2117.	1.0	65
67	A multinational registry to study the characteristics and outcomes of heart failure patients: The global congestive heart failure (G-CHF) registry. <i>American Heart Journal</i> , 2020, 227, 56-63.	1.2	24
68	The association of long-term outcome and biological sex in patients with acute heart failure from different geographic regions. <i>European Heart Journal</i> , 2020, 41, 1357-1364.	1.0	47
69	The Status of Specialized Ambulatory Heart Failure Care in Canada: A Joint Canadian Heart Failure Society and Canadian Cardiovascular Society Heart Failure Guidelines Survey. <i>CJC Open</i> , 2020, 2, 151-160.	0.7	10
70	The burden of non-cardiac comorbidities and association with clinical outcomes in an acute heart failure trial—Insights from ASCEND-HF. <i>European Journal of Heart Failure</i> , 2020, 22, 1022-1031.	2.9	27
71	Vericiguat in Patients with Heart Failure and Reduced Ejection Fraction. <i>New England Journal of Medicine</i> , 2020, 382, 1883-1893.	13.9	753
72	Circulating troponin and further left ventricular ejection fraction improvement in patients with previously recovered left ventricular ejection fraction. <i>ESC Heart Failure</i> , 2020, 7, 2725-2733.	1.4	7

#	ARTICLE	IF	CITATIONS
73	Cardiovascular disease burden in adult patients with cancer: An 11-year nationwide population-based cohort study. <i>International Journal of Cardiology</i> , 2020, 317, 167-173.	0.8	25
74	Underrepresentation of Women in Cardiovascular Randomized Clinical Trials. <i>Canadian Journal of Cardiology</i> , 2020, 36, 969.e7-969.e8.	0.8	5
75	A Novel In-hospital Congestion Score to Risk Stratify Patients Admitted for Worsening Heart Failure (from ASCEND-HF). <i>Journal of Cardiovascular Translational Research</i> , 2020, 13, 540-548.	1.1	5
76	Substance and Substrate. <i>Circulation</i> , 2020, 141, 362-366.	1.6	16
77	CCS/CHFS Heart Failure Guidelines: Clinical Trial Update on Functional Mitral Regurgitation, SGLT2 Inhibitors, ARNI in HFpEF, and Tafamidis in Amyloidosis. <i>Canadian Journal of Cardiology</i> , 2020, 36, 159-169.	0.8	89
78	Assessment of Limitations to Optimization of Guideline-Directed Medical Therapy in Heart Failure From the GUIDE-IT Trial. <i>JAMA Cardiology</i> , 2020, 5, 757.	3.0	74
79	Elevated Blood Pressure and Associations with Sodium Intake Among Multiethnic Youth in Edmonton, Canada: Findings from WHY ACT NOW. <i>High Blood Pressure and Cardiovascular Prevention</i> , 2020, 27, 239-249.	1.0	3
80	The Effect of Carotid Chemoreceptor Inhibition on Exercise Tolerance in Chronic Heart Failure. <i>Frontiers in Physiology</i> , 2020, 11, 195.	1.3	4
81	Press 1 to Speak to a Representative. <i>Circulation: Cardiovascular Quality and Outcomes</i> , 2020, 13, e007297.	0.9	0
82	Is incentivising stroke prevention therapy in atrial fibrillation the key?. <i>Heart</i> , 2019, 105, 4-5.	1.2	1
83	2017 Guidelines for the management of heart failure by pharmacists. <i>Canadian Pharmacists Journal</i> , 2019, 152, 301-316.	0.4	1
84	Screening and Initiating Supportive Care in Patients With Heart Failure. <i>Frontiers in Cardiovascular Medicine</i> , 2019, 6, 151.	1.1	5
85	Sodium Glucose Cotransporter-2 Inhibition and Cardiorenal Protection. <i>Journal of the American College of Cardiology</i> , 2019, 74, 2511-2524.	1.2	54
86	Trends in the Explanatory or Pragmatic Nature of Cardiovascular Clinical Trials Over 2 Decades. <i>JAMA Cardiology</i> , 2019, 4, 1122.	3.0	32
87	Natriuretic Peptide Response and Outcomes in Chronic Heart Failure With Reduced Ejection Fraction. <i>Journal of the American College of Cardiology</i> , 2019, 74, 1205-1217.	1.2	54
88	Quantification of lung water in heart failure using cardiovascular magnetic resonance imaging. <i>Journal of Cardiovascular Magnetic Resonance</i> , 2019, 21, 58.	1.6	14
89	A Population-Based Study of Device Eligibility, Use, and Reasons for Nonimplantation in Patients at Heart Function Clinics. <i>CJC Open</i> , 2019, 1, 173-181.	0.7	2
90	Empirical Insights When Defining the Population Burden of Atrial Fibrillation and Oral Anticoagulation Utilization Using Administrative Data. <i>Canadian Journal of Cardiology</i> , 2019, 35, 1412-1415.	0.8	12

#	ARTICLE	IF	CITATIONS
91	Creating order out of chaos: quality of care in heart failure. <i>Heart</i> , 2019, 105, 429-430.	1.2	2
92	The Relationship Between Heart-Failure Hospitalization and Mortality in Patients Receiving Transcatheter Aortic Valve Replacement. <i>Canadian Journal of Cardiology</i> , 2019, 35, 413-421.	0.8	11
93	Rationale and Design of the VITALITY-HFpEF Trial. <i>Circulation: Heart Failure</i> , 2019, 12, e005998.	1.6	33
94	External Validation and Refinement of Emergency Heart Failure Mortality Risk Grade Risk Model in Patients With Heart Failure in the Emergency Department. <i>CJC Open</i> , 2019, 1, 123-130.	0.7	7
95	External Validation of the H ₂ F-PEF Model in Diagnosing Patients With Heart Failure and Preserved Ejection Fraction. <i>Circulation</i> , 2019, 139, 2377-2379.	1.6	44
96	High vs. low oxygen therapy in patients with acute heart failure: HiLo-HF pilot trial. <i>ESC Heart Failure</i> , 2019, 6, 667-677.	1.4	16
97	Incremental costs of high intensive care utilisation in patients hospitalised with heart failure. <i>European Heart Journal: Acute Cardiovascular Care</i> , 2019, 8, 660-666.	0.4	4
98	Frequency, predictors, and prognosis of ejection fraction improvement in heart failure: an echocardiogram-based registry study. <i>European Heart Journal</i> , 2019, 40, 2110-2117.	1.0	63
99	Clinical factors related to morbidity and mortality in high-risk heart failure patients: the GUIDE predictive model and risk score. <i>European Journal of Heart Failure</i> , 2019, 21, 770-778.	2.9	36
100	Elevated pre-transplant left ventricular end-diastolic pressure increases primary graft dysfunction risk in double lung transplant recipients. <i>Journal of Heart and Lung Transplantation</i> , 2019, 38, 710-718.	0.3	12
101	The Effects of Resveratrol in Patients with Cardiovascular Disease and Heart Failure: A Narrative Review. <i>International Journal of Molecular Sciences</i> , 2019, 20, 904.	1.8	116
102	Update on the diagnosis and management of acute heart failure. <i>Current Opinion in Cardiology</i> , 2019, 34, 202-206.	0.8	6
103	Efficacy and Safety of Apixaban Versus Warfarin in Patients With Atrial Fibrillation and Extremes in Body Weight. <i>Circulation</i> , 2019, 139, 2292-2300.	1.6	78
104	Heart failure treatment and the art of medical decision making. <i>European Journal of Heart Failure</i> , 2019, 21, 1510-1514.	2.9	5
105	Titration and Tolerability of Sacubitril/Valsartan for Patients With Heart Failure in Clinical Practice. <i>Journal of Cardiovascular Pharmacology</i> , 2019, 73, 149-154.	0.8	14
106	NT-proBNP Goal Achievement Is Associated With Significant Reverse Remodeling and Improved Clinical Outcomes in HFrEF. <i>JACC: Heart Failure</i> , 2019, 7, 158-168.	1.9	65
107	Frailty modelling for multitype recurrent events in clinical trials. <i>Statistical Modelling</i> , 2019, 19, 140-156.	0.5	4
108	Insights on the Use of Twitter at the Canadian Cardiovascular Congress. <i>Canadian Journal of Cardiology</i> , 2018, 34, 813.e7-813.e8.	0.8	4

#	ARTICLE	IF	CITATIONS
109	Interaction of Body Mass Index on the Association Between Nâ€¢Terminalâ€¢Proâ€¢bâ€¢Type Natriuretic Peptide and Morbidity and Mortality in Patients With Acute Heart Failure: Findings From ASCENDâ€¢HF (Acute Study) Tj ETQq1 Association, 2018, 7, .	1.6	12
110	Use of Direct Oral Anticoagulants in Canadian Primary Care Practice 2010â€¢2015: A Cohort Study From the Canadian Primary Care Sentinel Surveillance Network. Journal of the American Heart Association, 2018, 7, .	1.6	17
111	Sudden cardiac death after acute heart failure hospital admission: insights from ASCENDâ€¢HF. European Journal of Heart Failure, 2018, 20, 525-532.	2.9	29
112	Is Time of the Essence? The Impact of Time of Hospital Presentation in Acute Heart Failure. JACC: Heart Failure, 2018, 6, 298-307.	1.9	4
113	Effects of supplemental oxygen therapy in patients with suspected acute myocardial infarction: a meta-analysis of randomised clinical trials. Heart, 2018, 104, 1691-1698.	1.2	34
114	A prospective evaluation of the established criteria for heart failure with preserved ejection fraction using the Alberta HEART cohort. ESC Heart Failure, 2018, 5, 19-26.	1.4	10
115	A Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial of the Efficacy and Safety of the Oral Soluble Guanylate Cyclase Stimulator. JACC: Heart Failure, 2018, 6, 96-104.	1.9	141
116	Relationship between baseline systolic blood pressure and long-term outcomes in acute heart failure patients treated with TRVO27: an exploratory subgroup analysis of BLAST-AHF. Clinical Research in Cardiology, 2018, 107, 170-181.	1.5	27
117	Prediction of Early Adverse Events in Emergency Department Patients With Acute Heart Failure: A Systematic Review. Canadian Journal of Cardiology, 2018, 34, 168-179.	0.8	16
118	Aetiology, timing and clinical predictors of early vs. late readmission following index hospitalization for acute heart failure: insights from ASCENDâ€¢HF. European Journal of Heart Failure, 2018, 20, 304-314.	2.9	42
119	Obesity paradox on outcome in atrial fibrillation maintained even considering the prognostic influence of biomarkers: insights from the ARISTOTLE trial. Open Heart, 2018, 5, e000908.	0.9	12
120	Effects of age, gender, and risk-factors for heart failure on native myocardial T1 and extracellular volume fraction using the SASHA sequence at 1.5T. Journal of Magnetic Resonance Imaging, 2018, 48, spcone-spcone.	1.9	0
121	Economic and Quality-of-Life Outcomes of Natriuretic Peptide-Guided Therapy for Heart Failure. Journal of the American College of Cardiology, 2018, 72, 2551-2562.	1.2	20
122	Acute Coronary Syndromes and Heart Failure Critical Care Units Utilization and Outcomes in Teaching and Community Hospitals: A National Population-Based Analysis. Canadian Journal of Cardiology, 2018, 34, 1365-1368.	0.8	2
123	Relationship Between Enrolling Country Income Level and Patient Profile, Protocol Completion, and Trial End Points. Circulation: Cardiovascular Quality and Outcomes, 2018, 11, e004783.	0.9	13
124	Canadian Cardiovascular Harmonized National Guidelines Endeavour (C-CHANGE) guideline for the prevention and management of cardiovascular disease in primary care: 2018 update. Cmaj, 2018, 190, E1192-E1206.	0.9	39
125	Impact of contrast echocardiography on accurate discrimination of specific degree of left ventricular systolic dysfunction and comparison with cardiac magnetic resonance imaging. Echocardiography, 2018, 35, 1746-1754.	0.3	10
126	Oxygen therapy in acute myocardial infarctions: do we need to re-evaluate its necessity?. Expert Review of Cardiovascular Therapy, 2018, 16, 693-694.	0.6	1

#	ARTICLE	IF	CITATIONS
127	Rate pressure product and the components of heart rate and systolic blood pressure in hospitalized heart failure patients with preserved ejection fraction: Insights from ASCEND-HF. <i>Clinical Cardiology</i> , 2018, 41, 945-952.	0.7	22
128	Trends in Noncardiovascular Comorbidities Among Patients Hospitalized for Heart Failure. <i>Circulation: Heart Failure</i> , 2018, 11, e004646.	1.6	134
129	Examining the Influence of Component Outcomes on the Composite at the Design Stage. <i>Circulation: Cardiovascular Quality and Outcomes</i> , 2018, 11, e004419.	0.9	1
130	Implantable cardioverter-defibrillators in heart failure patients with reduced ejection fraction and diabetes. <i>European Journal of Heart Failure</i> , 2018, 20, 1031-1038.	2.9	24
131	Influence of hospital volume on outcomes for patients with heart failure: Evidence from a Canadian national cohort study. <i>American Heart Journal</i> , 2018, 202, 148-150.	1.2	17
132	Rationale and design of the Study of Dietary Intervention Under 100 MMOL in Heart Failure (SODIUM-HF). <i>American Heart Journal</i> , 2018, 205, 87-96.	1.2	11
133	Reply to McClure et al. "Reader Commentary on 2017 Comprehensive Update of the Canadian Cardiovascular Society Guidelines for the Management of Heart Failure. <i>Canadian Journal of Cardiology</i> , 2018, 34, 813.e3.	0.8	0
134	Relation of Volume Overload to Clinical Outcomes in Acute Heart Failure (From ASCEND-HF). <i>American Journal of Cardiology</i> , 2018, 122, 1506-1512.	0.7	16
135	Use of Biomarkers to Predict Specific Causes of Death in Patients With Atrial Fibrillation. <i>Circulation</i> , 2018, 138, 1666-1676.	1.6	34
136	Effects of age, gender, and risk factors for heart failure on native myocardial T ₁ and extracellular volume fraction using the SASHA sequence at 1.5T. <i>Journal of Magnetic Resonance Imaging</i> , 2018, 48, 1307-1317.	1.9	9
137	The high cost of critical care unit over-utilization for patients with NSTEMI ACS. <i>American Heart Journal</i> , 2018, 202, 84-88.	1.2	19
138	Composite End Points in Clinical Trials of Heart Failure Therapy. <i>Circulation: Heart Failure</i> , 2017, 10, .	1.6	14
139	Interprovincial Differences in Canadian Coronary Care Unit Resource Use and Outcomes. <i>Canadian Journal of Cardiology</i> , 2017, 33, 166-169.	0.8	13
140	Diabetes and heart failure in the crosshairs: where is the target?. <i>European Journal of Heart Failure</i> , 2017, 19, 66-68.	2.9	0
141	Association Between Diabetes During Pregnancy and Peripartum Cardiomyopathy: A Population-Level Analysis of 309,825 Women. <i>Canadian Journal of Cardiology</i> , 2017, 33, 911-917.	0.8	14
142	Identifying Low-Risk Patients for Early Discharge From Emergency Department Without Using Subjective Descriptions of Chest Pain: Insights From Providing Rapid Out of Hospital Acute Cardiovascular Treatment (PROACT) 3 and 4 Trials. <i>Academic Emergency Medicine</i> , 2017, 24, 691-700.	0.8	2
143	Letter by Brown and Ezekowitz Regarding Article, "Development and Evolution of a Hierarchical Clinical Composite End Point for the Evaluation of Drugs and Devices for Acute and Chronic Heart Failure: A 20-Year Perspective" <i>Circulation</i> , 2017, 135, e889-e891.	1.6	4
144	Characterization of hemodynamically stable acute heart failure patients requiring a critical care unit admission: Derivation, validation, and refinement of a risk score. <i>American Heart Journal</i> , 2017, 188, 127-135.	1.2	5

#	ARTICLE	IF	CITATIONS
145	Navigating Choices Among a Sea of Comorbidities. Journal of the American College of Cardiology, 2017, 69, 2380-2382.	1.2	0
146	Biased ligand of the angiotensin II type 1 receptor in patients with acute heart failure: a randomized, double-blind, placebo-controlled, phase IIB, dose ranging trial (BLAST-AHF). European Heart Journal, 2017, 38, 2364-2373.	1.0	102
147	Impact of Current Versus Previous Cardiac Resynchronization Therapy Guidelines on the Proportion of Patients With Heart Failure Eligible for Therapy. JACC: Heart Failure, 2017, 5, 388-392.	1.9	11
148	Multitype Events and the Analysis of Heart Failure Readmissions. Circulation: Cardiovascular Quality and Outcomes, 2017, 10, .	0.9	2
149	Hospitalization for Recently Diagnosed Versus Worsening Chronic Heart Failure. Journal of the American College of Cardiology, 2017, 69, 3029-3039.	1.2	69
150	Dietary Self-management in Heart Failure: High Tech or High Touch?. Current Treatment Options in Cardiovascular Medicine, 2017, 19, 19.	0.4	5
151	2016 AHA/ACC Clinical Performance and Quality Measures for Prevention of Sudden Cardiac Death. Journal of the American College of Cardiology, 2017, 69, 712-744.	1.2	23
152	Body Weight Change During and After Hospitalization for Acute Heart Failure: Patient Characteristics, Markers of Congestion, and Outcomes. JACC: Heart Failure, 2017, 5, 1-13.	1.9	84
153	2016 AHA/ACC Clinical Performance and Quality Measures for Prevention of Sudden Cardiac Death: A Report of the American College of Cardiology/American Heart Association Task Force on Performance Measures. Circulation: Cardiovascular Quality and Outcomes, 2017, 10, e000022.	0.9	9
154	The Impact and Implications of Twitter for Cardiovascular Medicine. Journal of Cardiac Failure, 2017, 23, 266-267.	0.7	16
155	Multidisciplinary Approach to Novel Therapies in Cardio-Oncology Research (MANTICORE 101 Breast): A Randomized Trial for the Prevention of Trastuzumab-Associated Cardiotoxicity. Journal of Clinical Oncology, 2017, 35, 870-877.	0.8	292
156	Subclinical Pulmonary Edema Is Associated With Reduced Exercise Capacity in HFpEF and HFrEF. Journal of the American College of Cardiology, 2017, 70, 1827-1828.	1.2	11
157	Effect of Natriuretic Peptide-Guided Therapy on Hospitalization or Cardiovascular Mortality in High-Risk Patients With Heart Failure and Reduced Ejection Fraction. JAMA - Journal of the American Medical Association, 2017, 318, 713.	3.8	386
158	Ivabradine in Heart Failure. Circulation: Heart Failure, 2017, 10, .	1.6	23
159	Letter by Kaul et al Regarding Article, "Age-Specific Trends in Incidence, Mortality, and Comorbidities of Heart Failure in Denmark, 1995 to 2012". Circulation, 2017, 136, 884-885.	1.6	0
160	2017 Comprehensive Update of the Canadian Cardiovascular Society Guidelines for the Management of Heart Failure. Canadian Journal of Cardiology, 2017, 33, 1342-1433.	0.8	503
161	Heart Failure in Young Adults Is Associated With High Mortality: A Contemporary Population-Level Analysis. Canadian Journal of Cardiology, 2017, 33, 1472-1477.	0.8	28
162	Differentiating heart failure phenotypes using sex-specific transcriptomic and proteomic biomarker panels. ESC Heart Failure, 2017, 4, 301-311.	1.4	28

#	ARTICLE	IF	CITATIONS
163	A network analysis to compare biomarker profiles in patients with and without diabetes mellitus in acute heart failure. <i>European Journal of Heart Failure</i> , 2017, 19, 1310-1320.	2.9	53
164	Hyperkalemia, Sacubitril/Valsartan, and Mineralocorticoid Antagonists in Patients With Heart Failure. <i>JAMA Cardiology</i> , 2017, 2, 86.	3.0	1
165	Comparison of two commonly used clinical cognitive screening tests to diagnose mild cognitive impairment in heart failure with the golden standard European Consortium Criteria. <i>International Journal of Cardiology</i> , 2017, 228, 558-562.	0.8	31
166	Power and Sample Size Estimation for Nonparametric Composite Endpoints: Practical Implementation using Data Simulations. <i>Journal of Modern Applied Statistical Methods</i> , 2017, 16, 215-230.	0.2	2
167	Cognitive decline in heart failure. <i>Heart Failure Reviews</i> , 2016, 21, 661-673.	1.7	57
168	Salt in the diet in patients with heart failure. <i>Current Opinion in Cardiology</i> , 2016, 31, 196-203.	0.8	13
169	The clinical course of health status and association with outcomes in patients hospitalized for heart failure: insights from ASCEND-HF. <i>European Journal of Heart Failure</i> , 2016, 18, 306-313.	2.9	36
170	Insights into the importance of the electrocardiogram in patients with acute heart failure. <i>European Journal of Heart Failure</i> , 2016, 18, 1032-1040.	2.9	22
171	Cost Effectiveness of Eplerenone for the Treatment of Systolic Heart Failure with Mild Symptoms in Alberta, Canada. <i>American Journal of Cardiovascular Drugs</i> , 2016, 16, 365-376.	1.0	7
172	Liver function tests in patients with acute heart failure and associated outcomes: insights from ASCEND-HF. <i>European Journal of Heart Failure</i> , 2016, 18, 424-432.	2.9	45
173	Nesiritide in patients hospitalized for acute heart failure: does timing matter? Implication for future acute heart failure trials. <i>European Journal of Heart Failure</i> , 2016, 18, 684-692.	2.9	14
174	Chronic Oral Study of Myosin Activation to Increase Contractility in Heart Failure (COSMIC-HF): a phase 2, pharmacokinetic, randomised, placebo-controlled trial. <i>Lancet</i> , The, 2016, 388, 2895-2903.	6.3	229
175	The current and future financial burden of hospital admissions for heart failure in Canada: a cost analysis. <i>CMAJ Open</i> , 2016, 4, E365-E370.	1.1	73
176	Changes in dietary intake and nutritional status associated with a significant reduction in sodium intake in patients with heart failure. A sub-analysis of the SODIUM-HF pilot study. <i>Clinical Nutrition ESPEN</i> , 2016, 11, e26-e32.	0.5	24
177	The "obesity paradox"™ in atrial fibrillation: observations from the ARISTOTLE (Apixaban for Reduction in) Tj ETQq1 1 0.784314 rgB 2869-2878.	1.0	194
178	Heterogeneity across one disease, two drugs, three trials, and four guidelines: are we further ahead?. <i>European Journal of Heart Failure</i> , 2016, 18, 1244-1247.	2.9	0
179	Letter by McAlister and Ezekowitz Regarding Article, "Temporal Trends and Variation in Early Scheduled Follow-Up After a Hospitalization for Heart Failure: Findings From Get With the Guidelines-Heart Failure". <i>Circulation: Heart Failure</i> , 2016, 9, .	1.6	0
180	Influence of Clinical Trial Site Enrollment on Patient Characteristics, Protocol Completion, and End Points. <i>Circulation: Heart Failure</i> , 2016, 9, .	1.6	15

#	ARTICLE	IF	CITATIONS
181	Early Follow-Up After a Heart Failure Exacerbation. <i>Circulation: Heart Failure</i> , 2016, 9, .	1.6	49
182	Apixaban 5 mg Twice Daily and Clinical Outcomes in Patients With Atrial Fibrillation and Advanced Age, Low Body Weight, or High Creatinine. <i>JAMA Cardiology</i> , 2016, 1, 673.	3.0	81
183	Arrival by ambulance in acute heart failure: insights into the mode of presentation from Acute Studies of Nesiritide in Decompensated Heart Failure (ASCEND-HF). <i>BMJ Open</i> , 2016, 6, e010201.	0.8	11
184	Geographic Differences in Patients in a Global Acute Heart Failure Clinical Trial (from the ASCEND-HF) <i>TJ ETQq0 0 0 rgBT /Overlock 10 Tf</i>	0.7	26
185	Factors Associated With Natriuretic Peptide Testing in Patients Presenting to Emergency Departments With Suspected Heart Failure. <i>Canadian Journal of Cardiology</i> , 2016, 32, 986.e1-986.e8.	0.8	9
186	Oxygen Therapy in Patients With Acute Heart Failure. <i>JACC: Heart Failure</i> , 2016, 4, 783-790.	1.9	62
187	Alignment of site versus adjudication committee-based diagnosis with patient outcomes: Insights from the Providing Rapid Out of Hospital Acute Cardiovascular Treatment 3 trial. <i>Clinical Trials</i> , 2016, 13, 140-148.	0.7	13
188	Torsemide Versus Furosemide in Patients With Acute Heart Failure (from the ASCEND-HF Trial). <i>American Journal of Cardiology</i> , 2016, 117, 404-411.	0.7	47
189	Acute Treatment With Omecamtiv Mecarbil to Increase Contractility in Acute Heart Failure. <i>Journal of the American College of Cardiology</i> , 2016, 67, 1444-1455.	1.2	191
190	Coenzyme Q10 and Heart Failure. <i>Circulation: Heart Failure</i> , 2016, 9, e002639.	1.6	108
191	Dichotomous Relationship Between Age and 30-Day Death or Rehospitalization in Heart Failure Patients Admitted With Acute Decompensated Heart Failure: Results From the ASCEND-HF Trial. <i>Journal of Cardiac Failure</i> , 2016, 22, 409-416.	0.7	9
192	Do stable non-ST-segment elevation acute coronary syndromes require admission to coronary care units?. <i>American Heart Journal</i> , 2016, 175, 184-192.	1.2	31
193	Composite End Points in Acute Heart Failure Research: Data Simulations Illustrate the Limitations. <i>Canadian Journal of Cardiology</i> , 2016, 32, 1356.e21-1356.e28.	0.8	9
194	Canadian Cardiovascular Society Quality Indicators for Heart Failure. <i>Canadian Journal of Cardiology</i> , 2016, 32, 1038.e5-1038.e9.	0.8	13
195	The Canadian Cardiovascular Society Heart Failure Companion: Bridging Guidelines to Your Practice. <i>Canadian Journal of Cardiology</i> , 2016, 32, 296-310.	0.8	86
196	Clinical outcomes of patients with diabetes and atrial fibrillation treated with apixaban: results from the ARISTOTLE trial. <i>European Heart Journal - Cardiovascular Pharmacotherapy</i> , 2015, 1, 86-94.	1.4	59
197	How to Do More With Less. <i>Circulation: Cardiovascular Quality and Outcomes</i> , 2015, 8, 460-462.	0.9	3
198	Providing Rapid Out of Hospital Acute Cardiovascular Treatment 4 (PROACT-4). <i>Journal of the American Heart Association</i> , 2015, 4, .	1.6	26

#	ARTICLE	IF	CITATIONS
199	Is heart rate a risk marker in patients with chronic heart failure and concomitant atrial fibrillation? Results from the <sc>MAGGIC</sc> meta-analysis. <i>European Journal of Heart Failure</i> , 2015, 17, 1182-1191.	2.9	48
200	The Prognostic Importance of Changes in Renal Function during Treatment for Acute Heart Failure Depends on Admission Renal Function. <i>PLoS ONE</i> , 2015, 10, e0138579.	1.1	12
201	Impact of Rural Residence on Warfarin Use and Clinical Events in Patients with Non-Valvular Atrial Fibrillation: A Canadian Population Based Study. <i>PLoS ONE</i> , 2015, 10, e0140607.	1.1	10
202	Worsening heart failure during hospitalization for acute heart failure: Insights from the Acute Study of Clinical Effectiveness of Nesiritide in Decompensated Heart Failure (ASCEND-HF). <i>American Heart Journal</i> , 2015, 170, 298-305.	1.2	38
203	Variation in Critical Care Unit Admission Rates and Outcomes for Patients With Acute Coronary Syndromes or Heart Failure Among High- and Low-Volume Cardiac Hospitals. <i>Journal of the American Heart Association</i> , 2015, 4, e001708.	1.6	42
204	Acute Heart Failure and Atrial Fibrillation: Insights From the Acute Study of Clinical Effectiveness of Nesiritide in Decompensated Heart Failure (ASCEND-HF) Trial. <i>Journal of the American Heart Association</i> , 2015, 4, e002092.	1.6	25
205	The Effects of Climate Change on Cardiac Health. <i>Cardiology</i> , 2015, 131, 209-217.	0.6	1,123
206	The 2014 Canadian Cardiovascular Society Heart Failure Management Guidelines Focus Update: Anemia, Biomarkers, and Recent Therapeutic Trial Implications. <i>Canadian Journal of Cardiology</i> , 2015, 31, 3-16.	0.8	96
207	Incorporating patient preferences into clinical trial design: Results of the Opinions of Patients on Treatment Implications of New Studies (OPTIONS) project. <i>American Heart Journal</i> , 2015, 169, 122-131.e22.	1.2	24
208	Peripheral chemoreceptor control of cardiovascular function at rest and during exercise in heart failure patients. <i>Journal of Applied Physiology</i> , 2015, 118, 839-848.	1.2	15
209	Heart Failure Therapeutics on the Basis of Biased Ligand of the Angiotensin-2 Type 1 Receptor. <i>JACC: Heart Failure</i> , 2015, 3, 193-201.	1.9	68
210	Loop diuretic dose adjustments after a hospitalization for heart failure: insights from <sc>ASCEND-HF</sc>. <i>European Journal of Heart Failure</i> , 2015, 17, 340-346.	2.9	22
211	Correlation between peak expiratory flow rate and NT-proBNP in patients with acute heart failure. An analysis from ASCEND-HF trial. <i>International Journal of Cardiology</i> , 2015, 182, 184-186.	0.8	2
212	The future of cardiovascular clinical research in North America and beyond—addressing challenges and leveraging opportunities through unique academic and grassroots collaborations. <i>American Heart Journal</i> , 2015, 169, 743-750.	1.2	15
213	Reply. <i>JACC: Heart Failure</i> , 2015, 3, 271-272.	1.9	0
214	Assessing the Use of International Classification of Diseases-10th Revision Codes From the Emergency Department for the Identification of Acute Heart Failure. <i>JACC: Heart Failure</i> , 2015, 3, 386-391.	1.9	33
215	Diuretic response in acute heart failure—an analysis from ASCEND-HF. <i>American Heart Journal</i> , 2015, 170, 313-321.e4.	1.2	110
216	Association Between Self-reported Adherence to a Low-Sodium Diet and Dietary Habits Related to Sodium Intake in Heart Failure Patients. <i>Journal of Cardiovascular Nursing</i> , 2015, 30, 58-65.	0.6	25

#	ARTICLE	IF	CITATIONS
217	Predictors of clinical outcomes in acute decompensated heart failure: Acute Study of Clinical Effectiveness of Nesiritide in Decompensated Heart Failure outcome models. <i>American Heart Journal</i> , 2015, 170, 290-297.e1.	1.2	57
218	Estimates of Dietary Sodium Consumption in Patients With Chronic Heart Failure. <i>Journal of Cardiac Failure</i> , 2015, 21, 981-988.	0.7	16
219	Heart failure guidelines fail. <i>Cmaj</i> , 2015, 187, 912.2-912.	0.9	0
220	Re. "Dietary fatty acids intake and mortality in patients with heart failure" Authors' response. <i>Nutrition</i> , 2015, 31, 1185-1186.	1.1	0
221	The long-term effects of dietary sodium restriction on clinical outcomes in patients with heart failure. The SODIUM-HF (Study of Dietary Intervention Under 100 mmol in Heart Failure): A pilot study. <i>American Heart Journal</i> , 2015, 169, 274-281.e1.	1.2	53
222	Early Management of Patients With Acute Heart Failure: State of the Art and Future Directions" A Consensus Document from the <sc>SAEM</sc>/<sc>HFSA</sc> Acute Heart Failure Working Group. <i>Academic Emergency Medicine</i> , 2015, 22, 94-112.	0.8	41
223	Early Management of Patients With Acute Heart Failure: State of the Art and Future Directions. A Consensus Document From the Society for Academic Emergency Medicine/Heart Failure Society of America Acute Heart Failure Working Group. <i>Journal of Cardiac Failure</i> , 2015, 21, 27-43.	0.7	73
224	Metabolomic Fingerprint of Heart Failure with Preserved Ejection Fraction. <i>PLoS ONE</i> , 2015, 10, e0124844.	1.1	150
225	Heart Failure Re-Admission: Measuring the Ever Shortening Gap between Repeat Heart Failure Hospitalizations. <i>PLoS ONE</i> , 2014, 9, e106494.	1.1	33
226	Hypotension During Hospitalization for Acute Heart Failure Is Independently Associated With 30-Day Mortality. <i>Circulation: Heart Failure</i> , 2014, 7, 918-925.	1.6	42
227	Nesiritide, Renal Function, and Associated Outcomes During Hospitalization for Acute Decompensated Heart Failure. <i>Circulation</i> , 2014, 130, 958-965.	1.6	41
228	Diabetes, impaired fasting glucose, and heart failure: Its not all about the sugar. <i>European Journal of Heart Failure</i> , 2014, 16, 1153-1156.	2.9	18
229	The association between meteorological events and acute heart failure: New insights from ASCEND-HF. <i>International Journal of Cardiology</i> , 2014, 177, 819-824.	0.8	9
230	The relationship between left ventricular ejection fraction and mortality in patients with acute heart failure: insights from the <sc>ASCENDâ€HF T</sc>rial. <i>European Journal of Heart Failure</i> , 2014, 16, 334-341.	2.9	56
231	Time to Energize Coenzyme Q 10 for Patients With Heart Failure? â—. <i>JACC: Heart Failure</i> , 2014, 2, 650-652.	1.9	10
232	Smoking status and survival: impact on mortality of continuing to smoke one year after the angiographic diagnosis of coronary artery disease, a prospective cohort study. <i>BMC Cardiovascular Disorders</i> , 2014, 14, 133.	0.7	20
233	Representativeness of RELAX-AHF Clinical Trial Population in Acute Heart Failure. <i>Circulation: Cardiovascular Quality and Outcomes</i> , 2014, 7, 259-268.	0.9	37
234	The Alberta Heart Failure Etiology and Analysis Research Team (HEART) study. <i>BMC Cardiovascular Disorders</i> , 2014, 14, 91.	0.7	27

#	ARTICLE	IF	CITATIONS
235	High-Sensitivity C-Reactive Protein in Acute Heart Failure: Insights From the ASCEND-HF Trial. <i>Journal of Cardiac Failure</i> , 2014, 20, 319-326.	0.7	57
236	Determinants of Early Readmission After Hospitalization for Heart Failure. <i>Canadian Journal of Cardiology</i> , 2014, 30, 612-618.	0.8	40
237	Influence of heart failure symptoms and ejection fraction on short- and long-term outcomes for older patients with non-ST-segment elevation myocardial infarction. <i>American Heart Journal</i> , 2014, 167, 267-273.e1.	1.2	13
238	Risk Stratification in Acute Heart Failure. <i>Canadian Journal of Cardiology</i> , 2014, 30, 312-319.	0.8	39
239	The 2013 Canadian Cardiovascular Society Heart Failure Management Guidelines Update: Focus on Rehabilitation and Exercise and Surgical Coronary Revascularization. <i>Canadian Journal of Cardiology</i> , 2014, 30, 249-263.	0.8	44
240	Acute decompensated heart failure patients admitted to critical care units: Insights from ASCEND-HF. <i>International Journal of Cardiology</i> , 2014, 177, 840-846.	0.8	14
241	Rates and reasons for device-based guideline eligibility in patients with heart failure. <i>Heart Rhythm</i> , 2014, 11, 1983-1990.	0.3	11
242	Rationale and Design of the GUIDE-IT Study. <i>JACC: Heart Failure</i> , 2014, 2, 457-465.	1.9	106
243	Trends in death attributed to myocardial infarction, heart failure and pulmonary embolism in Europe and Canada over the last decade. <i>QJM - Monthly Journal of the Association of Physicians</i> , 2014, 107, 813-820.	0.2	21
244	Dietary fatty acids intake and mortality in patients with heart failure. <i>Nutrition</i> , 2014, 30, 1366-1371.	1.1	22
245	Providing Rapid Out of Hospital Acute Cardiovascular Treatment 3 (PROACT-3). <i>Canadian Journal of Cardiology</i> , 2014, 30, 1208-1215.	0.8	11
246	Which risk score best predicts perioperative outcomes in nonvalvular atrial fibrillation patients undergoing noncardiac surgery?. <i>American Heart Journal</i> , 2014, 168, 60-67.e5.	1.2	21
247	Mortality Outcomes Among Status Aboriginals and Whites With Heart Failure. <i>Canadian Journal of Cardiology</i> , 2014, 30, 619-626.	0.8	9
248	Optimizing Therapy of Heart Failure in the Aging Population with Monitoring in Clinics. , 2014, , 85-93.		0
249	Association of global weather changes with acute coronary syndromes: gaining insights from clinical trials data. <i>International Journal of Biometeorology</i> , 2013, 57, 401-408.	1.3	8
250	Novel Pharmacologic Therapies in Development for Acute Decompensated Heart Failure. <i>Current Cardiology Reports</i> , 2013, 15, 329.	1.3	4
251	Effects of Nesiritide and Predictors of Urine Output in Acute Decompensated Heart Failure. <i>Journal of the American College of Cardiology</i> , 2013, 62, 1177-1183.	1.2	78
252	Similarities and Differences in Patient Characteristics Between Heart Failure Registries Versus Clinical Trials. <i>Current Heart Failure Reports</i> , 2013, 10, 373-379.	1.3	15

#	ARTICLE	IF	CITATIONS
253	Myocardial Deformation Analysis in Contrast Echocardiography: First Results Using Two-Dimensional Cardiac Performance Analysis. <i>Journal of the American Society of Echocardiography</i> , 2013, 26, 1282-1289.	1.2	7
254	Predictors of early dyspnoea relief in acute heart failure and the association with 30-day outcomes: findings from ASCEND-HF. <i>European Journal of Heart Failure</i> , 2013, 15, 456-464.	2.9	39
255	Left Ventricular Systolic Dysfunction, Heart Failure, and the Risk of Stroke and Systemic Embolism in Patients With Atrial Fibrillation. <i>Circulation: Heart Failure</i> , 2013, 6, 451-460.	1.6	136
256	The 2012 Canadian Cardiovascular Society Heart Failure Management Guidelines Update: Focus on Acute and Chronic Heart Failure. <i>Canadian Journal of Cardiology</i> , 2013, 29, 168-181.	0.8	176
257	Differences in Treatment, Outcomes, and Quality of Life Among Patients With Heart Failure in Canada and the United States. <i>JACC: Heart Failure</i> , 2013, 1, 523-530.	1.9	22
258	Neither Diabetes nor Glucose-Lowering Drugs Are Associated With Mortality After Noncardiac Surgery in Patients With Coronary Artery Disease or Heart Failure. <i>Canadian Journal of Cardiology</i> , 2013, 29, 423-428.	0.8	9
259	The relationship between meteorological conditions and index acute coronary events in a global clinical trial. <i>International Journal of Cardiology</i> , 2013, 168, 2315-2321.	0.8	13
260	Incidence of heart failure and mortality after acute coronary syndromes. <i>American Heart Journal</i> , 2013, 165, 379-385.e2.	1.2	80
261	Prognostic relevance of baseline pro- and anti-inflammatory markers in STEMI: An APEX AMI substudy. <i>International Journal of Cardiology</i> , 2013, 168, 2127-2133.	0.8	34
262	Acute Decompensated Heart Failure: Update on New and Emerging Evidence and Directions for Future Research. <i>Journal of Cardiac Failure</i> , 2013, 19, 371-389.	0.7	53
263	N-Terminal Pro-B-Type Natriuretic Peptide for Risk Assessment in Patients With Atrial Fibrillation. <i>Journal of the American College of Cardiology</i> , 2013, 61, 2274-2284.	1.2	191
264	Outcomes of apixaban vs. warfarin by type and duration of atrial fibrillation: results from the ARISTOTLE trial. <i>European Heart Journal</i> , 2013, 34, 2464-2471.	1.0	154
265	Practice-Level Variation in Use of Recommended Medications Among Outpatients With Heart Failure. <i>Circulation: Heart Failure</i> , 2013, 6, 1132-1138.	1.6	35
266	Global Variation in Quality of Care Among Patients Hospitalized With Acute Heart Failure in an International Trial. <i>Circulation: Cardiovascular Quality and Outcomes</i> , 2013, 6, 534-542.	0.9	25
267	The Systemic Inflammatory Response Syndrome in Patients With ST-Segment Elevation Myocardial Infarction*. <i>Critical Care Medicine</i> , 2013, 41, 2080-2087.	0.4	35
268	Changes in Heart Failure Outcomes After a Province-Wide Change in Health Service Provision A Natural Experiment in Alberta, Canada. <i>Circulation: Heart Failure</i> , 2013, 6, 76-82.	1.6	28
269	Do Countries or Hospitals With Longer Hospital Stays for Acute Heart Failure Have Lower Readmission Rates?. <i>Circulation: Heart Failure</i> , 2013, 6, 727-732.	1.6	103
270	Impact of physician continuity on death or urgent readmission after discharge among patients with heart failure. <i>Cmaj</i> , 2013, 185, E681-E689.	0.9	82

#	ARTICLE	IF	CITATIONS
271	Do Anticoagulants or Antiplatelet Drugs Have a Role in Treating Heart Failure in the Absence of Atrial Fibrillation?. <i>Clinical Pharmacology and Therapeutics</i> , 2013, 94, 435-438.	2.3	1
272	Routine versus selective cardiac magnetic resonance in non-ischemic heart failure â€œ OUTSMART-HF: study protocol for a randomized controlled trial (IMAGE-HF (heart failure) project 1-B). <i>Trials</i> , 2013, 14, 332.	0.7	5
273	Effect of low-dose dopamine on cardiorespiratory physiology in heart failure patients. <i>FASEB Journal</i> , 2013, 27, 928.6.	0.2	0
274	Acute Heart Failure. <i>Circulation: Heart Failure</i> , 2012, 5, 735-741.	1.6	27
275	Response to Letter Regarding Article, â€œMortality and Readmission of Patients With Heart Failure, Atrial Fibrillation, or Coronary Artery Disease Undergoing Noncardiac Surgery: An Analysis of 38 047 Patientsâ€œ. <i>Circulation</i> , 2012, 125, .	1.6	1
276	Testosterone Supplementation in Heart Failure. <i>Circulation: Heart Failure</i> , 2012, 5, 315-321.	1.6	166
277	Renal Dysfunction in Patients With Heart Failure With Preserved Versus Reduced Ejection Fraction. <i>Circulation: Heart Failure</i> , 2012, 5, 309-314.	1.6	152
278	The survival of patients with heart failure with preserved or reduced left ventricular ejection fraction: an individual patient data meta-analysis. <i>European Heart Journal</i> , 2012, 33, 1750-1757.	1.0	652
279	Heart Failure Is a Clinically and Densitometrically Independent Risk Factor for Osteoporotic Fractures: Population-Based Cohort Study of 45,509 Subjects. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2012, 97, 1179-1186.	1.8	50
280	Efficacy and safety of apixaban compared with warfarin according to patient risk of stroke and of bleeding in atrial fibrillation: a secondary analysis of a randomised controlled trial. <i>Lancet</i> , The, 2012, 380, 1749-1758.	6.3	175
281	Heart failure: can we define, assess, and treat diastolic heart failure?. <i>European Journal of Heart Failure</i> , 2012, 14, 713-715.	2.9	3
282	Indications for Cardiac Resynchronization Therapy: 2011 Update From the Heart Failure Society of America Guideline Committee. <i>Journal of Cardiac Failure</i> , 2012, 18, 94-106.	0.7	93
283	Update on Aldosterone Antagonists Use in Heart Failure With Reduced Left Ventricular Ejection Fraction Heart Failure Society of America Guidelines Committee. <i>Journal of Cardiac Failure</i> , 2012, 18, 265-281.	0.7	50
284	Predicting the risk of unplanned readmission or death within 30 days of discharge after a heart failure hospitalization. <i>American Heart Journal</i> , 2012, 164, 365-372.	1.2	139
285	Assessment of Dyspnea in Acute Decompensated Heart Failure. <i>Journal of the American College of Cardiology</i> , 2012, 59, 1441-1448.	1.2	35
286	DO COUNTRIES OR HOSPITALS WITH LONGER STAYS HAVE LOWER READMISSION RATES? FINDINGS FROM THE ASCEND-HF TRIAL. <i>Journal of the American College of Cardiology</i> , 2012, 59, E1029.	1.2	3
287	Baseline NT-proBNP and biomarkers of inflammation and necrosis in patients with ST-segment elevation myocardial infarction: insights from the APEX-AMI trial. <i>Journal of Thrombosis and Thrombolysis</i> , 2012, 34, 106-113.	1.0	22
288	The Timing of Implantable Cardioverter-Defibrillator Implantation in Patients with Heart Failure. <i>Current Cardiology Reports</i> , 2012, 14, 299-307.	1.3	1

#	ARTICLE	IF	CITATIONS
289	Trends in heart failure care: has the incident diagnosis of heart failure shifted from the hospital to the emergency department and outpatient clinics?. <i>European Journal of Heart Failure</i> , 2011, 13, 142-147.	2.9	116
290	Effect of Nesiritide in Patients with Acute Decompensated Heart Failure. <i>New England Journal of Medicine</i> , 2011, 365, 32-43.	13.9	1,133
291	The epidemiology of atrial fibrillation in adults depends on locale of diagnosis. <i>American Heart Journal</i> , 2011, 161, 986-992.e1.	1.2	38
292	The 2011 Canadian Cardiovascular Society Heart Failure Management Guidelines Update: Focus on Sleep Apnea, Renal Dysfunction, Mechanical Circulatory Support, and Palliative Care. <i>Canadian Journal of Cardiology</i> , 2011, 27, 319-338.	0.8	139
293	Apixaban versus Warfarin in Patients with Atrial Fibrillation. <i>New England Journal of Medicine</i> , 2011, 365, 981-992.	13.9	7,537
294	Meta-analysis: Cardiac Resynchronization Therapy for Patients With Less Symptomatic Heart Failure. <i>Annals of Internal Medicine</i> , 2011, 154, 401.	2.0	113
295	Carotid chemoreceptor modulation of blood flow during exercise in healthy humans. <i>Journal of Physiology</i> , 2011, 589, 6219-6230.	1.3	47
296	Do Anthropometric Indices Accurately Reflect Directly Measured Body Composition in Men and Women With Chronic Heart Failure?. <i>Congestive Heart Failure</i> , 2011, 17, 89-91.	2.0	23
297	The Correlation of Standard Heart Failure Assessment and Palliative Care Questionnaires in a Multidisciplinary Heart Failure Clinic. <i>Journal of Pain and Symptom Management</i> , 2011, 42, 379-387.	0.6	38
298	Rationale and design of the Multidisciplinary Approach to Novel Therapies in Cardiology Oncology Research Trial (MANTICORE 101 - Breast): a randomized, placebo-controlled trial to determine if conventional heart failure pharmacotherapy can prevent trastuzumab-mediated left ventricular remodeling among patients with HER2+ early breast cancer using cardiac MRI. <i>BMC Cancer</i> , 2011, 11, 318.	1.1	76
299	Use of oral proton pump inhibitors is not associated with harm in patients with chronic heart failure in an ambulatory setting. <i>European Journal of Heart Failure</i> , 2011, 13, 1211-1215.	2.9	8
300	Risk stratification schemes, anticoagulation use and outcomes: the risk-treatment paradox in patients with newly diagnosed non-valvular atrial fibrillation. <i>Heart</i> , 2011, 97, 2046-2050.	1.2	73
301	The Unrecognized Burden of Osteoporosis-Related Vertebral Fractures in Patients With Heart Failure. <i>Circulation: Heart Failure</i> , 2011, 4, 419-424.	1.6	39
302	Cardiac resynchronisation therapy is efficacious in patients with mild heart failure symptoms. <i>Evidence-Based Medicine</i> , 2011, 16, 138-139.	0.6	0
303	Ethnic differences in 1-year mortality among patients hospitalised with heart failure. <i>Heart</i> , 2011, 97, 1048-1053.	1.2	23
304	Patterns of Care and Outcomes Differ for Urban Versus Rural Patients With Newly Diagnosed Heart Failure, Even in a Universal Healthcare System. <i>Circulation: Heart Failure</i> , 2011, 4, 317-323.	1.6	95
305	Mortality and Readmission of Patients With Heart Failure, Atrial Fibrillation, or Coronary Artery Disease Undergoing Noncardiac Surgery. <i>Circulation</i> , 2011, 124, 289-296.	1.6	186
306	Resource Use in the Last 6 Months of Life Among Patients With Heart Failure in Canada. <i>Archives of Internal Medicine</i> , 2011, 171, 211.	4.3	65

#	ARTICLE	IF	CITATIONS
307	The Prevalence of Natural Health Product Use in Patients with Acute Cardiovascular Disease. <i>PLoS ONE</i> , 2011, 6, e19623.	1.1	19
308	Prediction of cardiogenic shock using plasma B-type natriuretic peptide and the N-terminal fragment of its pro-hormone concentrations in ST elevation myocardial infarction: An analysis from the ASSENT-4 Percutaneous Coronary Intervention Trial. <i>Critical Care Medicine</i> , 2010, 38, 1793-1801.	0.4	17
309	The epidemiology and management of elderly patients with myocardial infarction or heart failure. <i>Heart Failure Reviews</i> , 2010, 15, 407-413.	1.7	9
310	Association between obesity and health-related quality of life in patients with coronary artery disease. <i>International Journal of Obesity</i> , 2010, 34, 1434-1441.	1.6	43
311	A new pathway? Failure, fragility and fractures. <i>European Heart Journal</i> , 2010, 31, 9-11.	1.0	10
312	Association Between Direct Measures of Body Composition and Prognostic Factors in Chronic Heart Failure. <i>Mayo Clinic Proceedings</i> , 2010, 85, 609-617.	1.4	135
313	Testosterone Therapy in Women With Heart Failure. <i>Journal of the American College of Cardiology</i> , 2010, 56, 1317-1319.	1.2	7
314	HFSA 2010 Comprehensive Heart Failure Practice Guideline. <i>Journal of Cardiac Failure</i> , 2010, 16, e1-e2.	0.7	1,086
315	Executive Summary: HFSA 2010 Comprehensive Heart Failure Practice Guideline. <i>Journal of Cardiac Failure</i> , 2010, 16, 475-539.	0.7	267
316	Comparison of Direct Body Composition Assessment Methods in Patients With Chronic Heart Failure. <i>Journal of Cardiac Failure</i> , 2010, 16, 867-872.	0.7	26
317	Plasma N-terminal fragment of the prohormone B-type natriuretic peptide concentrations in relation to time to treatment and Thrombolysis in Myocardial Infarction (TIMI) flow: A substudy of the Assessment of the Safety and Efficacy of a New Treatment Strategy with Percutaneous Coronary Intervention (ASSENT IV-PCI) trial. <i>American Heart Journal</i> , 2010, 159, 131-140.	1.2	19
318	Predicting chronic left ventricular dysfunction 90 days after ST-segment elevation myocardial infarction: An Assessment of Pexelizumab in Acute Myocardial Infarction (APEX-AMI) Substudy. <i>American Heart Journal</i> , 2010, 160, 272-278.	1.2	29
319	Does silent myocardial infarction add prognostic value in ST-elevation myocardial infarction patients without a history of prior myocardial infarction? Insights from the Assessment of Pexelizumab in Acute Myocardial Infarction (APEX-AMI) Trial. <i>American Heart Journal</i> , 2010, 160, 671-677.	1.2	18
320	The 2010 Canadian Cardiovascular Society guidelines for the diagnosis and management of heart failure update: Heart failure in ethnic minority populations, heart failure and pregnancy, disease management, and quality improvement/assurance programs. <i>Canadian Journal of Cardiology</i> , 2010, 26, 185-202.	0.8	125
321	A Case of Dilated Cardiomyopathy Associated with 3-Hydroxy-3-Methylglutaryl-Coenzyme A (HMG CoA) Lyase Deficiency. <i>Case Reports in Medicine</i> , 2009, 2009, 1-3.	0.3	19
322	A Call to Action: Cardiac Palliative Care. <i>Journal of Palliative Medicine</i> , 2009, 12, 289-290.	0.6	1
323	Response to Letter Regarding Article, "Heart Failure Is a Risk Factor for Orthopedic Fracture: A Population-Based Analysis of 16 294 Patients". <i>Circulation</i> , 2009, 120, .	1.6	0
324	What Price to Pay?. <i>Circulation</i> , 2009, 119, 368-370.	1.6	2

#	ARTICLE	IF	CITATIONS
325	Reperfusion before percutaneous coronary intervention in ST-elevation myocardial infarction patients is associated with lower N-terminal pro-brain natriuretic peptide levels during follow-up, irrespective of pre-treatment with full-dose fibrinolysis. <i>European Heart Journal</i> , 2009, 30, 2213-2219.	1.0	4
326	The relationship between body mass index, treatment, and mortality in patients with established coronary artery disease: a report from APPROACH. <i>European Heart Journal</i> , 2009, 30, 2584-2592.	1.0	121
327	Standardizing care for acute decompensated heart failure in a large megatrial: The approach for the Acute Studies of Clinical Effectiveness of Nesiritide in Subjects with Decompensated Heart Failure (ASCEND-HF). <i>American Heart Journal</i> , 2009, 157, 219-228.	1.2	36
328	Declining In-Hospital Mortality and Increasing Heart Failure Incidence in Elderly Patients With First Myocardial Infarction. <i>Journal of the American College of Cardiology</i> , 2009, 53, 13-20.	1.2	309
329	Meta-analysis: β -Blocker Dose, Heart Rate Reduction, and Death in Patients With Heart Failure. <i>Annals of Internal Medicine</i> , 2009, 150, 784.	2.0	426
330	Canadian Cardiovascular Society Consensus Conference guidelines on heart failure, update 2009: Diagnosis and management of right-sided heart failure, myocarditis, device therapy and recent important clinical trials. <i>Canadian Journal of Cardiology</i> , 2009, 25, 85-105.	0.8	79
331	Irbesartan did not reduce all-cause death or CV hospitalization in heart failure and preserved ejection fraction. <i>Annals of Internal Medicine</i> , 2009, 150, JC5.	2.0	2
332	Comparison of One-Year Outcome (Death and Rehospitalization) in Hospitalized Heart Failure Patients With Left Ventricular Ejection Fraction \geq 50% Versus Those With Ejection Fraction $<$ 50%. <i>American Journal of Cardiology</i> , 2008, 102, 79-83.	0.7	21
333	Canadian Cardiovascular Society Consensus Conference guidelines on heart failure – 2008 update: Best practices for the transition of care of heart failure patients, and the recognition, investigation and treatment of cardiomyopathies. <i>Canadian Journal of Cardiology</i> , 2008, 24, 21-40.	0.8	93
334	Heart Failure Is a Risk Factor for Orthopedic Fracture. <i>Circulation</i> , 2008, 118, 1946-1952.	1.6	136
335	Aldosterone blockade and left ventricular dysfunction: a systematic review of randomized clinical trials. <i>European Heart Journal</i> , 2008, 30, 469-477.	1.0	145
336	Acute heart failure in the emergency department: Short and long-term outcomes of elderly patients with heart failure. <i>European Journal of Heart Failure</i> , 2008, 10, 308-314.	2.9	104
337	Cardiac Resynchronization Therapy for Patients With Left Ventricular Systolic Dysfunction. <i>JAMA - Journal of the American Medical Association</i> , 2007, 297, 2502.	3.8	497
338	Insights into the change in brain natriuretic peptide after ST-elevation myocardial infarction (STEMI): why should it be better than baseline? This paper is one of a selection of papers published in this Special Issue, entitled Young Investigators' Forum.. <i>Canadian Journal of Physiology and Pharmacology</i> , 2007, 85, 173-178.	0.7	10
339	Systematic Review: Implantable Cardioverter Defibrillators for Adults with Left Ventricular Systolic Dysfunction. <i>Annals of Internal Medicine</i> , 2007, 147, 251.	2.0	146
340	Anemia in Patients With Advanced Heart Failure. <i>Journal of the American College of Cardiology</i> , 2007, 49, 2301.	1.2	13
341	N-terminal pro-brain natriuretic peptide and the timing, extent and mortality in ST elevation myocardial infarction. <i>Canadian Journal of Cardiology</i> , 2006, 22, 393-397.	0.8	25
342	Proportion of Patients Followed in a Specialized Heart Failure Clinic Needing an Implantable Cardioverter Defibrillator as Determined by Applying Different Trial Eligibility Criteria. <i>American Journal of Cardiology</i> , 2006, 97, 882-885.	0.7	18

#	ARTICLE	IF	CITATIONS
343	Challenges in Systematic Reviews of Therapeutic Devices and Procedures. <i>Annals of Internal Medicine</i> , 2005, 142, 1100.	2.0	61
344	Impact of specialist follow-up in outpatients with congestive heart failure. <i>Cmaj</i> , 2005, 172, 189-194.	0.9	151
345	Time-dependent analysis in CHF follow-up. <i>Cmaj</i> , 2005, 173, 238-239.	0.9	0
346	Angiotensin receptor blockers and risk of myocardial infarction: systematic review. <i>BMJ: British Medical Journal</i> , 2005, 331, 873.	2.4	67
347	The interaction among sex, hemoglobin and outcomes in a specialty heart failure clinic. <i>Canadian Journal of Cardiology</i> , 2005, 21, 165-71.	0.8	20
348	The Use of β -Blockers in a Tertiary Care Heart Failure Clinic. <i>Archives of Internal Medicine</i> , 2004, 164, 769.	4.3	43
349	Renal Insufficiency and Heart Failure. <i>Circulation</i> , 2004, 109, 1004-1009.	1.6	651
350	Usefulness of spironolactone in a specialized heart failure clinic. <i>American Journal of Cardiology</i> , 2004, 94, 443-447.	0.7	28
351	The association among renal insufficiency, pharmacotherapy, and outcomes in 6,427 patients with heart failure and coronary artery disease. <i>Journal of the American College of Cardiology</i> , 2004, 44, 1587-1592.	1.2	331
352	Therapeutic exercise for individuals with heart failure: special attention to older women with heart failure. <i>Journal of Cardiac Failure</i> , 2004, 10, 165-173.	0.7	19
353	Systematic Review: Cardiac Resynchronization in Patients with Symptomatic Heart Failure. <i>Annals of Internal Medicine</i> , 2004, 141, 381.	2.0	274
354	Anemia Is Common in Heart Failure and Is Associated With Poor Outcomes. <i>Circulation</i> , 2003, 107, 223-225.	1.6	789
355	Implantable Cardioverter Defibrillators in Primary and Secondary Prevention. <i>Annals of Internal Medicine</i> , 2003, 138, 445.	2.0	234
356	Defibrillators and Sudden Death. <i>Annals of Internal Medicine</i> , 2003, 139, W-85.	2.0	0
357	Stroke: strategies for primary prevention. <i>American Family Physician</i> , 2003, 68, 2379-86.	0.1	15
358	The waiting game: facing the consequences. <i>Cmaj</i> , 2002, 167, 1247-8.	0.9	1
359	Successful cryopreservation of rat islets using ethylene glycol. <i>Transplantation Proceedings</i> , 1997, 29, 1983.	0.3	3
360	CRYOPRESERVATION OF RAT PANCREATIC ISLETS. <i>Transplantation</i> , 1997, 64, 1065-1070.	0.5	23

#	ARTICLE	IF	CITATIONS
361	Surprise outcome for SODIUM-HF. , 0, , .		0